NCT00539591View on ClinicalTrials.gov

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 9, 2008

Primary Completion Date

June 30, 2015

Study Completion Date

May 31, 2026

Conditions
Malignant Melanoma
Interventions
DRUG

Peginterferon alfa-2b

Given either IV or SQ. Therapeutic drug class: interferon.

DRUG

Temozolomide

Given PO. Therapeutic drug class: antineoplastic agent.

DRUG

Recombinant interferon alfa-2b

Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon

Trial Locations (3)

38105

St. Jude Children's Research Hospital, Memphis

77030

The Children's Cancer Hospital at UT M.D. Anderson Cancer Center, Houston

92123

Rady Children's Hospital, San Diego

Sponsors

Collaborators (1)

Schering-Plough
All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER